(vianews) - shares of boiron (cac 40: boi.pa) jumped by a staggering 32.19% in 21 sessions from €38.05 to €50.30 at 11:52 est on thursday, following the last session's downward trend. cac 40 is rising 0.45% to €7,366.18, after four successive sessions in a row of gains.
boiron's last close was €50.50, 5.08% under its 52-week high of €53.20.
about boiron
boiron sa manufactures and sells homeopathic medicines in france, rest of europe, north america, and internationally. the company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. it also provides homeopathic specialties comprising oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; stodal and stodaline for treating coughs; arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; camilia for the treatment of teething problems for babies; sédatif pc to treat anxiety and emotional, and minor sleep disorders; coryzalia for the treatment of cold symptoms and rhinitis; homéoptic to treat eye discomfort and irritation due to various causes for adults and children; homéovox for vocal disorders; homéoplasmine for treating irritated skin and redness; varésol to treat symptoms of chickenpox; and arnicare arthritis for use in the treatment of benign trauma pain. in addition, it offers dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; covid self-tests and rapid antigenic tests; labiameo, that used to treat outbreaks of localized cold sores; and convameo to treat physical and mental asthenia. the company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. boiron sa was founded in 1932 and is headquartered in messimy, france.
earnings per share
as for profitability, boiron has a trailing twelve months eps of €2.89.
pe ratio
boiron has a trailing twelve months price to earnings ratio of 17.4. meaning, the purchaser of the share is investing €17.4 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.13%.volume
today's last reported volume for boiron is 4011 which is 4.44% below its average volume of 13798.
more news about boiron (boi.pa).